Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Womens Health Issues. 2009 Nov 26;20(1):35. doi: 10.1016/j.whi.2009.09.001

Figure 1. Cost-effectiveness analysis of VIA and Pap smears.

Figure 1

Cost-effectiveness of no screening, screening with Pap smears (3-visits), and screening with VIA (2-visits). Effectiveness is measured as the percentage of cancer cases avoided in the 10 years following screening. Costs are represented in U.S. dollars. VIA demonstrated extended dominance over the Pap smear.